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Abstract
Sentinel lymph node (SLN) biopsy has emerged as a preferred method for axillary lymph node
staging of breast cancer, and imaging the SLN in three-dimensional space is a prerequisite for the
biopsy. Conventional SLN mapping techniques based on the injection of an organic dye or a
suspension of radioactive colloids suffer from invasive surgical operation for visual detection of
the dye or hazardous radioactive components and low spatial resolution of Geiger counters in
detecting the radioactive colloids. This work systematically investigates the use of gold nanocages
(AuNCs) as a novel class of optical tracers for noninvasive SLN imaging by photoacoustic (PA)
tomography in a rat model. The transport of AuNCs in a lymphatic system and uptake by the
sentinel lymph node were evaluated by PA tomography on the axillary region of a rat.
Quantification of AuNCs accumulated in the lymph node was achieved by correlating the data
from PA imaging with the results from inductively-coupled plasma mass spectrometry. Several
parameters were systematically evaluated and optimized, including the concentration, size, and
surface charge of the AuNCs. These results are critical to the further development of this AuNC-
based PA tomography system for noninvasive SLN imaging, providing valuable information for
metastatic cancer staging.
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The metastatic spread of a tumor occurs by invading the adjacent tissue and disseminating
cancerous cells through the lymphatic system into the blood stream.1 The closest lymph
node that receives the drainage from a tumor is known as the sentinel lymph node (SLN),
which represents the most likely first location of metastatic spread. To reduce the side
effects of axillary lymph node dissection,2 sentinel lymph node biopsy (SLNB) is widely
performed and has become the standard for axillary staging in breast cancer patients.3
Although SLNB with blue dyes (such as lymphazurin or methylene blue) or radioactive
colloidal tracers has an identification rate of more than 90%, these methods involve invasive
surgical operations and use carcinogenic ionizing radiation. They may also fail to identify
axillary diseases owing to a high false negative rate of 5–10%.4 Furthermore, they can pose
a risk of postoperative complications, such as seroma formation, lymphedema, and motion
limitation.5
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Recently, ultrasound-guided fine needle aspiration biopsy (FNAB) has been clinically
evaluated as a minimally invasive procedure.6 This technique requires accurate positioning
of the SLN, which initiates studies to develop accurate, nonionizing, and noninvasive
methods for SLN mapping. Photoacoustic (PA) tomography is such a technique with
remarkable resolution, which is based on the optical absorption contrast mechanism.7,8
Since the spatial resolution of this technique is determined by ultrasound parameters, the
imaging depth can be extended to the optical quasidiffusive or diffusive regime while
maintaining high resolution. By using diffusive photons, the maximum PA imaging depth
can be pushed up to 50 mm in biological tissues.9 Our previous work successfully
demonstrated PA SLN imaging by using clinically available organic dyes.10,11 Although this
dye-based PA imaging system has been demonstrated with a depth capability of ~31 mm,
satisfactory spatial resolution, and clinical potential, the drawback of this system lies in that
the dye molecules are rather small (<2 nm), and thus they can easily transport into the
echelon lymph nodes, causing a high possibility of false positives.12
In contrast, gold nanocages (AuNCs), a novel class of nanostructures characterized by
hollow interiors and ultrathin, porous walls, have proper size range (30–100 nm) to ensure
sufficiently fast migration and sufficient duration of trapping in SLN for imaging.8 The
localized surface plasmon resonance (LSPR) peak of AuNCs can also be precisely tuned to
the near-infrared (NIR) region from 700 to 900 nm (the so-called transparent window), in
which the attenuation of light by blood and soft tissue is relatively low.13 In addition,
AuNCs can be easily bioconjugated with various types of ligands such as antibodies,
peptides, and nucleic acids to target specific receptors,14,15 potentially eliminating the nee d
for invasive axillary staging procedures in addition to providing noninvasive SLN mapping.
Other attractive features of AuNCs include bio-inertness, large absorption cross sections
(almost five orders of magnitude greater than those of conventional organic dyes),16 and the
ability to encapsulate therapeutic drugs, which offers a great benefit for theranostic
applications.17 In a previous publication, we have demonstrated a proof-of-concept use of
AuNCs for SLN imaging by PA tomography, where an intradermal injection of 100 μL of 2
nM AuNC solution was performed on the forepaw pad of a rat, and the SLN was identified
with enhanced contrast and good spatial resolution.18 Many parameters associated with the
AuNCs, including the minimum requirement on the concentration and injected volume and
the influence of particle size, shape, and surface characteristics on their transport kinetics
and uptakes by lymph nodes, still need to be examined and optimized before thissystem can
be further considered for potential clinical use.
Here we quantitatively evaluated the transport of AuNCs in the lymphatic system and the
uptake by lymph nodes through PA imaging on a rat model. The influences of concentration,
particle size, and surface charge were all systematically examined. The amounts of AuNCs
accumulated in the SLNs were quantified by inductively-coupled plasma mass spectrometry
(ICP-MS) analysis of the dissected lymph nodes after the rats had been euthanized. The
results provide valuable information for further development of this AuNC-based PA
imaging system for noninvasive lymph node mapping.
RESULTS AND DISCUSSION
The main objective of this study is to quantitatively investigate the PA contrast enhancement
in SLNs provided by AuNCs with different concentrations, sizes, and surface characteristics.
The influences of these parameters were examined by using suspensions of AuNCs with a
range of concentrations, two different sizes (50 and 30 nm in edge length), and three
different surface charges (negative, positive, and neutral). Figure 1, A and B shows typical
transmission electron microscopy (TEM) images of AuNCs with an edge length of 50 and
30 nm, respectively. Figure 1C shows the UV-vis extinction spectra of 50- and 30-nm
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AuNCs. The locations of their LSPR peaks were slightly different, centered at 760 and 730
nm, respectively. During PA imaging, the laser wavelength was tuned to overlap with the
corresponding absorption peak. Except for the experiments involving comparison of particle
size, the AuNCs used in all studies were 50 nm in edge length. The surface of the as-
synthesized AuNCs is typically covered with poly(vinyl pyrrolidone) (PVP, MW≈55,000), a
biocompatible polymer. To investigate the effect of surface charges, the PVP layer was
replaced by heterofunctional poly(ethylene glycol) (PEG, MW≈5,000) with one end
terminated in the sulfhydryl group and the other terminated by the amine (-NH2), methoxy (-
OMe), or carboxylic acid (-COOH) group, to generate positive, neutral, or negative surface
charges, respectively. The as-prepared AuNCs covered by PVP were used in all experiments
except the study of surface charges. The injection volume was kept the same at 100 μL for
all experiments while the concentration of AuNCs was varied. PA imaging of the axillary
region of a Sprague-Dawley rat (250–300 g) was performed at different time points after
intradermal injection of an aqueous suspension of AuNCs in the left forepaw pad, and the
amplitude change of PA signals was then monitored as a function of time.
We first tested the ex vivo sensitivity of our current deep-reflection mode PA imaging
system by using gelatin phantoms based on a mixture of gelatin and AuNCs.18,19 As shown
in Figure 2, PA signals from the gelatin phantom containing AuNCs at a concentration as
low as 10 pM could still be detected with a signal-to-noise ratio (SNR) of ~2.2 dB. This
detection limit corresponds to ~2×105 (or 3.3×10−19 mol) AuNCs per imaging voxel. If we
assume the typical volume of SLN in a rat is ~23.6 mm3 (the SLN is approximated as an
ellipsoid of 3 mm × 5 mm × 3 mm), this detection sensitivity indicates that only ~1.3×108
(or 2.1×10−16 mol) AuNCs need to enter the lymph node to provide sufficient signals for
imaging. The noise equivalent concentration (i.e., the concentration that provides a SNR of
unity) is calculated to be ~4.5 pM. In addition, the ex vivo experiment showed that no
structural change to the nanocages was observed after expossure to the laser (determined by
the TEM image), indicating that the nanocages were stable during the PA imaging. The
power density of the laser applied was 35 mW/cm2, and was kept at this level for all the in
vivo studies.
To evaluate the in vivo sensitivity of our PA system and AuNCs for lymph node imaging,
we intradermally injected an aqueous suspension of AuNCs at a specific, decreasing
concentration (100, 50, and 20 pM) at a dose of 100 μL (this corresponds to an amount of
2.2×107, 1.1×107, and 0.55×107 AuNCs per gram of body weight, respectively) on the left
forepaw pad of a rat and then the left axillary region of the rat was noninvasively imaged
using the PA system. The field of view that possibly contains SLN was chosen based on our
previous experience with lymph node imaging.10, 18, 20 Before the injection of AuNCs, PA
images were acquired as control images (Fig. 3, A, D and G), revealing the vasculature
within ~3 mm below the skin surface. After the injection of AuNCs, a series of PA images
were obtained up to 120 min post-injection. It can be observed that the SLNs started to
appear at 5 min after the injection of 100 pM (Fig. 3B) and 50 pM (Fig. 3E) AuNC
suspensions while the SLN was not detected at 5 min after the injection of 20 pM AuNCs
(Fig. 3H). As time elapsed, the PA signals gradually increased and the SLNs, including the
case with the injection of 20 pM AuNCs, could be clearly observed at 120 min post-
injection (Fig. 3, C, F and I). Note that the minimum concentration of 20 pM we used here
for PA SLN imaging in a rat model was about 100 times less than the value (2 nM) reported
in our previous work,18 greatly reducing the potential toxicity of AuNCs. It is also worth
pointing out that the drainage of AuNCs to lymph nodes was much faster than that of Au
nanorods, even at a relatively low injection concentration. In our previous study, it took
more than 20 h for Au nanorods (10 nm in diameter and 41 nm in length) with an injection
concentration of 1 μM to be observed at SLNs.21 These results suggest that AuNCs should
serve as a better diagnostic imaging agent than Au nanorods for SLN imaging.
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We also performed in vivo PA SLN imaging in two additional rats at each concentration,
following the same procedure. The PA signal enhancements in SLNs were summarized as a
function of time (Fig. 4A). Each data point was normalized against the PA signal from the
corresponding adjacent blood vessels (BV) acquired before the injection of AuNCs. This
normalization method was also applied to the experiments described in other sections. We
found that the PA signal enhancement increased with increasing injection concentration. The
enhancement also increased with post-injection time, indicating the gradual accumulation of
AuNCs in SLNs. For example, after the injection of 100 pM AuNCs, the enhancement was
182% ± 12% at t=5 min, and then gradually increased to 355% ± 24% at t=120 min post-
injection. For the group with 20 pM AuNCs, the SLNs in two of the three rats were not even
detected at t=120 min post-injection. This high false negative rate indicates that we had
reached the in vivo detection limit of the PA system. Note that the standard errors for PA
signal enhancement at 5 and 30 min post-injection in the group of 50 pM AuNCs injection
were still relatively high compared to those with 100 pM sample, indicating that a 100 pM
suspension of AuNCs at a dose of 100 μL (2.2×107 AuNCs per gram of body weight) seems
to be the best candidate to start with for SLN imaging. We further quantified the number of
AuNCs accumulated in the SLN by ICP-MS analysis of the excised node. The accumulated
amount of AuNCs in SLN for the 100 pM sample was approximately 2 and 7.5 times higher
than the 50 pM and 20 pM samples, respectively (Fig. 4B). The average numbers of AuNCs
in SLN per mass at 120 min post-injection of 20, 50 and 100 pM of AuNCs were about
(0.86±0.74)×1010, (3.25±1.07)×1010, and (6.43±0.94)×1010 AuNCs/g, respectively, which
were qualitatively consistent with the trend revealed by PA enhancement shown in Figure
4A. According to our measurements, about 18% of the injected 50 pM and 100 pM AuNCs
had been accumulated in the SLN at t=120 min post injection, while about 12% of the
injected 20 pM AuNCs had been accumulated in the SLN. Based on the ICP-MS data, there
were about twice as many AuNCs in the SLN for the 100 pM sample than for the 50 pM
sample, while the PA signal enhancement for the 100 pM sample only showed a slight
increase. This discrepancy can be attributed to two reasons: i) the AuNCs were actually not
evenly distributed in the SLN. This phenomenon was observed in our previous report on
SLN imaging.18 The edges of the SLN were found to contain more nanocages than the
central portion of the SLN. Therefore, if some parts of the SLN contained a small amount of
AuNCs that generated PA signals lower than the background, we would not be able to detect
them; ii) the PA signal is sensitive to the imaging depth. If some parts of the SLN were away
from the focus and the PA signal from AuNCs was lower than the background, the signal
could not be detected either.
The SLNs of rats are located at ~2 mm below the skin surface. In humans, the mean depth of
SLNs is ~12 mm underneath the skin.18 Therefore, it is necessary to demonstrate the
minimal dose of AuNCs at the clinical depth by using the same PA imaging modality. Here,
we used chicken breast tissues as biological phantoms. The previously reported penetration
depth for 1/e decay in chicken breast tissue was ~0.94 cm at the wavelength of 760 nm,22
while the 1/e penetration depth at 785 nm in human breast was measured to be ~0.89 cm.23
Similar to the previous experiments, after the SLN of a rat in the group of 100 pM AuNCs
was identified (Fig. 5A), a chicken breast tissue of 5 mm thick was placed on top of the
axillary surface of the rat, and a PA image was acquired at 150 min post-injection. The SLN
of the rat could be obviously identified from this image, and the total depth of the SLN was
now ~7 mm (Fig. 5B). With the addition of a second layer of chicken breast tissue, an
imaging depth of ~12 mm was achieved by acquiring a PA image at 180 min post-injection
(Fig. 5C), and the SLN can still be imaged with a good contrast. In the B-scan image (Fig.
5D), the depth information of the SLN is clearly shown with ~7 dBSNR.
An ideal mapping agent for lymphoscintigraphy should have proper size: on one hand, it
should be small enough to rapidly drain to lymphatic vessels and then transport to lymph
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nodes; on the other hand, it should be large enough to stay within the lymph nodes during
the imaging process. Particles smaller than 5 nm could easily leak into blood capillaries or
migrate to echelon lymph nodes and thus cause false positives,24 while particles larger than
100 nm are believed to be trapped in the interstitial compartment for a long period of time,
and are thus unable to transport to lymph nodes fast enough for lymphoscintigraphy.25
Therefore, it is critical to identify an optimal size range for the AuNCs in order to have
sufficiently fast migration and sufficient duration of trapping for SLN imaging.
We compared the PA enhancements in SLNs as a function of time using AuNCs with edge
lengths of 50 nm and 30 nm, respectively (Fig. 6A). We performed the in vivo PA imaging
in 3 rats for each group. Note that the surface of the as-prepared AuNCs was covered with
PVP, and thus the hydrodynamic diameter of the AuNCs measured by dynamic light
scattering (DLS) was about 97.1 nm, so we did not choose AuNCs with an edge length
larger than 50 nm. Additionally, nanoparticles with larger size (>50 nm) are known to
exhibit short circulation times in blood,26 making them less useful in diagnostic imaging.
The injection concentrations for both the 30-nm and 50-nm AuNCs were 200 pM (at a dose
of 100 μL), as the SLN could hardly be detected with the injection of 30-nm AuNCs at a
concentration of 100 pM. The amounts of Au injected for 30-nm and 50-nm AuNCs were
calculated to be about 7.5 ng and 22.7 ng per gram of body weight, respectively. Both
curves show that SLNs could be detected at 5 min post injection, and the PA signal
enhancement kept increasing in the following 120 min. It can be seen that the 50-nm AuNCs
showed higher signal enhancement (about 150% to 170%) than the 30-nm sample. This
difference can be ascribed to the fact that the 30-nm AuNCs had a smaller optical absorption
cross section than the 50-nm AuNCs, generating weaker PA signals. We have also measured
the absorption cross sections of these AuNCs using a PA-based method developed in our
groups.16 The absorption cross section of the 50-nm AuNCs at 760 nm was found to be
about 2.1 times higher than that of the 30-nm AuNCs at 730 nm. Figure 6B shows a
comparison of the accumulation of 50-nm and 30-nm AuNCs in SLNs as a function of post-
injection time calculated from the PA signals. Since the PA signal is directly proportional to
the absorption coefficient (μa) of the AuNCs,16 the accumulation of AuNCs can be
calculated according to the equation: Nnano=μa,nano/σa,nano, where Nnano is the concentration
of the AuNCs (number of particles per m3)and σ a,nano is the absorption cross section (m2)
of the nanocages. Each data point was then normalized against the accumulation of 50-nm
AuNCs in SLN at 5 min post-injection. It can be seen that the 30-nm AuNCs transported
into the SLN faster than the 50-nm AuNCs and showed alarger amount of accumulation in
the SLN. The ICP-MS data in Figure 6C indicate that the average number of 30-nm AuNCs
in the excised SLN per mass at 120 min post-injection was about 1.8 times higher than that
of the 50-nm AuNCs, (14.5 ± 1.0) × 1010 vs. (8.0 ± 0.6) × 1010 AuNCs/g, which is
consistent with the trend of accumulation derived from the PA signals. The dose of Au
accumulated in the SLN for 30-nm and 50-nm AuNCs at 120 min post-injection was about
2.5 × 10−5 g and 4.1 × 10−5 g per gram of SLN, respectively. Even though the 30-nm
AuNCs showed a larger amount of accumulation in SLN based on the particle number, the
amount of Au content in SLN for the 50-nm AuNCs was about 1.6 times higher than that for
the 30-nm AuNCs.
Early studies on the transport kinetics and lymphatic uptake of particles showed that surface
characteristics, such as charge and hydrophobicity, could affect the rate of particle drainage
from the injection site to lymph nodes and their distribution within the lymphatic system.25
Therefore, it is important to study the transport behaviors of AuNCs with different surface
charges. We replaced the PVP layer on the AuNCs with SH-PEG5000-X (X=OMe, NH2, or
COOH). Table 1 summarized the hydrodynamic diameters and zeta-potentials of the
PEGylated AuNCs. It can be observed that the zeta-potential of AuNCs covered with SH-
PEG5000-OMe was about −7.2 mV, and thus the surface charge is considered as neutral. The
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zeta-potentials of AuNCs covered with SH-PEG5000-NH2 and SH-PEG5000-COOH were
around +12.5 mV and −16.8 mV, giving a relatively positive and negative surface charge,
respectively. Following the same procedure, we performed in vivo SLN imaging using
AuNCs modified with different surface charges. For comparison, each group had 3 rats and
the injection concentration was 200 pM instead of 100 pM for all 3 groups, because the SLN
could be hardly detected at 60 min after the injection of AuNCs with positive charges at a
concentration of 100 pM. Figure 7 shows typical PA images acquired before as well as 5
min and 60 min after the injection of AuNCs modified with different surface charges. Unlike
the other two groups, AuNCs with negative charges accumulated not only in the SLN but
also in the adjacent lymphatic vessels. The lymphatic vessels began to show up in PA
images at 5 min post injection (Fig. 7B) and the AuNCs could be trapped there for 60 min
(Fig. 7C). It is known that lymphatic vessels play an important role in lymphatic
metastasis,27,28 providing crucial prognostic information. Cancer cells can exploit these
vascular systems by expressing growth factors, altering the normal pattern of angiogenesis
and lymphatic vessel growth, creating conduits for tumor metastasis. As a result, the ability
to target and image aberrant drainage patterns is of clinical significance. However, studies
on lymphatic vessels have been hindered by technical limitations.29 The AuNCs with
negative charges can potentially be used as a good contrast agent for lymphangiogenesis
imaging. In addition, AuNCs with positive charges also showed a unique feature. It took 30
to 60 min, a much longer time than the other two groups, to transport to SLNs and
accumulate enough amounts for PA imaging (Fig. 7, D-F). Figure 8A shows PA signal
enhancement in SLNs as a function of time after the injection of AuNCs with different
surface charges. It can be seen that the signal enhancement originating from AuNCs with
positive chargesis much lower than that from the neutral AuNCs, especially in the first 60
min post injection, indicating a much slower transport rate to lymph nodes. As for the PA
enhancement from the AuNCs with negative charges, it was also lower (about 50% to 60%)
than the neutral AuNCs, but higher (about 150% to 160%) than the positive AuNCs in the
first 60 min post injection, and then leveled off. The ICP-MS data in Figure 8B show that
the average number of AuNCs in the excised SLN per mass at 240 min post injection
decreased in the order of neutral > positive > negative, which is consistent with the trend for
PA signal enhancement shown in Figure 8A.
We also found that the AuNCs were not only able to transport to the SLN, but also further
down to the second and third axillary lymph nodes of a rat. As shown in Figure 9, C and D,
both in vivo and ex vivo PA images clearly show the accumulation of nanocages in all three
lymph nodes of the rat after the injection of AuNCs at a relatively higher concentration (500
pM) at 72 h post injection (no transport to the second and third axillary lymph nodes had
been observed by PA imaging after the injection of 100 pM or 200 pM nanocages). Taken
together, these features can probably be used to design AuNCs with switchable surface
charges for noninvasive axillary lymph node staging of breast cancer by taking advantage of
their different transport kinetics in lymph nodes. For example, we can conjugate the surface
of AuNCs with an enzyme-sensitive peptide which can be cleaved by enzymes (e.g., matrix
metalloproteases, a recognized biomarker associated with cancer-cell invasion and
metastasis) overexpressed by cancer cells in the metastatic lymph node.30 As such, the
surface charges on the AuNCs will be different before and after the enzyme cleavage, and
the transport rates of AuNCs between lymph nodes will be different for patients with
different stages of metastatic cancer. In addition, we can also attach fluorescence dyes to the
surface of AuNCs via an enzyme-cleavable peptide.31 The dye molecules will be cleaved
and released from the surface of the nanocage in the presence of a protease, and thus
fluorescence will be recovered. In practice, the distribution of AuNCs in lymph nodes can be
mapped by PA imaging while the protease activity can be monitored by fluorescence
spectroscopy, providing critical information for the diagnosis of breast cancer metastasis.
Related researches are currently underway. With regard to the improvement for PA imaging,
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the system we used for this study employed a single ultrasonic transducer and a 10 Hz pulse-
repetition-rate laser system, and thus the scanning time for a three-dimensional image was
about 24 min with 0.2 mm and 0.4 mm step-sizes. For future studies, employing an
ultrasonic array system and a higher pulse-repetition-frequency laser system can
dramatically improve the temporal resolution. We are currently developing a handheld,
array-based PA system for future clinical use.32,33
CONCLUSION
We have quantitatively evaluated the transport of AuNCs in a lymphatic system and their
uptakes by lymph nodes in a rat model through PA imaging. We systematically examined
and optimized a number of experimental parameters including the concentration, size, as
well as surface characteristics of the AuNCs. We reduced the concentration of injected
AuNCs down to 100 pM (20 times lower than our previous proof-to-concept report, greatly
reducing the potential toxicity of AuNCs) for SLN imaging at a depth of ~12 mm (the depth
of SLN in human) while keeping a sufficient SNR. It was found that the 30-nm AuNCs
exhibited a faster transport rate and a larger amount of accumulation in the SLN than the 50-
nm AuNCs, but the latter generated stronger PA signals due to a larger optical absorption
cross section. This result indicates that the 50-nm AuNCs seem to be a better contrast agent
than the 30-nm AuNCs for SLN imaging by PA tomography. As for AuNCs with different
surface charges, their transport rates to SLNs decreased in the order of neutral > negative >
positive. In addition, AuNCs with negative charges could be trapped in lymphatic vessels,
making them potentially useful as contrast agents for lymphangiogenesis by PA imaging.
We also found that the AuNCs were not only able to transport to the SLN, but can also
travel farther to the second and third axillary lymph nodes of a rat. These results can serve as
guidelines for choosing optimal experimental parameters of AuNCs in metastatic lymph
nodes mapping and other biomedical applications by noninvasive PA imaging.
METHODS
Synthesis and Surface Modification of AuNCs
The AuNCs were synthesized using the galvanic replacement reaction between Ag
nanocubes and chloroauric acid in water according to our published protocol.34 In a typical
synthesis, an aqueous solution of HAuCl4 (0.75 mM) was slowly titrated (at a rate of 45 mL/
h using a syringe pump) into an aqueous suspension of Ag nanocubes placed in a three-neck
flask at 90 °C. The extent of replacement could be readily monitored by taking UV-vis
spectra of aliquots sampled from the solution. To obtain different surface charges, the
nanocages were derivatized with SH-PEG5000-X (X=OMe, NH2, and COOH; all from
Laysan Bio; Mw≈5,000). In a typical process, 0.1 mL of HS-PEG5000-X aqueous solution
(0.1 mM) and 0.1 mL of AuNCs aqueous suspension (1 nM in terms of particles) were
added to 2.8 mL deionized water. The mixture was kept stirring at 4°C overnight. After that,
the mixture was centrifuged at 14,000 rpm for 15 min and the supernatant was decanted to
remove the excess PEG. The PEGylated-AuNCs were then washed with water twice and re-
suspended in water at a concentration of 200 pM (in terms of particles) for in vivostudies.
The PA Imaging System
A deep reflection-mode PA imaging system was used (Scheme 1 in ref. 19) for all PA
experiments. A tunable Ti:sapphire laser (LT-2211A; Lotis TII, Minsk, Belarus) pumped by
a Q-switched Nd:YAG (LS-2137; Lotis TII) laser was used for excitation, providing <15-ns
pulse duration and a 10-Hz pulse repetition rate. A dark-field ring-shaped illumination was
adopted to reduce the surface PA signal generation.35 The light energy on the sample
surface was controlled to be less than the American National Standards Institute standard for
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maximum permissible exposure. Two wavelengths, 760 nm and 730 nm, were used for PA
imaging to match the absorption peak positions of the 50-nm and 30-nm AuNCs,
respectively. A 5-MHz central frequency, spherically focused ultrasonic transducer (V308;
Panametrics-NDT, Waltham, MA, USA) was used to acquire the generated PA signals. The
5 MHz ultrasonic transducer yields axial and transverse resolutions of 150 and 560 μm,
respectively. The signal was amplified by a low -noise amplifier (5072PR; Panametrics-
NDT) and recorded using a digital oscilloscope (TDS 5054, Tektronix, Beaverton, OR). A
photodiode (SM05PD1A, Thorlabs, Newton, NJ) was used to compensate for the energy
instability of laser pulses. A linear translation stage (XY-6060, Danaher Motion, Radford,
VA) was used for raster scanning to obtain three-dimensional (3D) PA data. The signal was
not averaged for any image to shorten the data acquisition time. By measuring PA
amplitudes according to the arrival times, one-dimensional depth-resolved images (A-lines)
are acquired. Additional raster scanning along a transverse direction provides two-
dimensional depth-resolved images (B-scans), consisting of multiple A-scans, and further
scanning along the other traverse direction provides 3D images. The acquired 3D raw data
can be processed as a maximum amplitude projection (MAP)—a projection of the maximum
PA amplitude along each A-line onto the corresponding plane. Typical scanning values were
as follows: field of view, 20 × 20 mm; voxel dimension, 0.2 × 0.4 mm; laser pulse repetition
rate, 10 Hz; and acquisition time, ~24 min. The transducer was located inside a water
container with an opening of 5 × 5 cm at the bottom, sealed beneath a photoacoustically
transparent clear membrane. The rats or gelatin phantom samples made from a mixture of
gelatin solution and AuNCs were placed under the membrane, and ultrasonic gel was used
for ultrasound coupling.
Animal Handling
All animal experiments were in compliance with the Washington University Institutional
Animal Care and Use Committee. Sprague–Dawley rats weighting 200–300 g (Harlan,
Indianapolis, IN) were anesthetized with a mixture of ketamine (87 mg/kg) and xylazine (13
mg/kg) at a dose of 0.15 mL per 100 g body weight. The hair in the left axillary region was
removed by gentle clipping and depilatory cream before imaging. PA imaging was acquired
before and after intradermal injection of AuNC solution (0.1 mL) in the left forepaw pad.
Full anesthesia of the animal was maintained throughout the experiment by using vaporized
isoflurane (1 L/min of oxygen and 0.75% isoflurane) and vitals were monitored by a pulse
oximeter (NOMIN Medical, 2000SA). The body temperatures of the rats were maintained
with a water heating pad. After data acquisition, the rats were euthanized by overdosed
pentobarbital and SLNs were dissected for ICP-MS measurements.
ICP-MS of AuNCs in Dissected Lymph Nodes
The excised lymph nodes were weighed and then were completely digested with 5 mL of
aqua regia in a 50 mL beaker at boiling temperature. The solution was evaporated to 1 mL
and subsequently diluted to 15 mL with deionized water. Samples were passed through a
0.45-mm filter to remove any undigested debris prior to ICP-MS measurement. The analysis
of Au content was performed with ICP-MS (Perkin Elmer, Elan DRC II), and the
concentration of Au ions was converted to the concentration of nanocages once the
geometric dimensions of the nanocage had been determined from TEM images.
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TEM images of Au nanocages (AuNCs) with average edge lengths of (A) 50 nm and (B) 30
nm; (C) UV-vis extinction spectra of aqueous suspensions of AuNCs with edge lengths of
50 nm (solid line) and 30 nm (dashed line).
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PA signals recorded from gelatin phantoms containing AuNCs at various concentrations
(R2=0.99), showing that the detection limit of AuNCs (50 nm in edge length) was less than
10 pM, or 2×105 (or 3.3×10−19 mol) AuNCs per imaging voxel, for the PA system. If we
assume the typical volume of the SLN in a rat is ~23.6 mm3 (the SLN is approximated as an
ellipsoid of 3 mm × 5 mm × 3 mm), this detection sensitivity indicates that only ~1.3×108
(or 2.1×10−16mol) AuNCs need to enter the lymph node to provide sufficient signals for im
aging.
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PA images of the axillary region of rats acquired at 0, 5, and 120 min after injection of the
AuNCs with different concentrations. (A, D, G) PA images before injection of the AuNCs;
(B, E, H) PA images 5 min after the injection of AuNCs at different concentrations. The
SLNs started to appear except for the 20 pM sample; (C, F, I) PA images 120 min after the
injection of AuNCs at different concentrations. The three concentrations correspond to
amounts of 2.2×107, 1.1×107, and 0.55×107 AuNCs per gram of body weight, respectively.
BV, blood vessels; SLN, sentinel lymph node.
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(A) PA signal enhancement in SLNs as a function of time after the injection of AuNCs at
different concentrations (n=3 rats for each group): 100, 50, and 20 pM, respectively. Each
data point was normalized against the PA signal from the corresponding adjacent blood
vessels before the injection of AuNCs. (B) Average numbers of AuNCs accumulated in the
SLNs dissected at 120 min post injection, as measured using ICP-MS. Here NLN denotes the
number of AuNCs per unit lymph nodemass (g ).
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PAimaging of SLN in a rat after the injection of 100 pMAuNCs. The PA images were
acquired (A) at 120 min post-injection with no chicken breast tissue added, (B) at 150 min
post injection with one layer (thickness: 5 mm) of chicken breast tissue added, and (C) at
180 min post injection with two layers (total thickness: 10 mm) of chicken breast tissue
added. (D) PA B-scan along the dashed line in (C), showing the SLN located at a depth of
~12 mm. SLN, sentinel lymph node.
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(A) PA signal enhancement in SLNs after the injection of 50-nm and 30-nm AuNCs with the
same concentration and dose (200 pM and 100 μL) as a function of post-injection time (n=3
rats for each group), respectively. (B) Accumulation of the 50-nm and 30-nm AuNCs in
SLNs as a function of post-injection time calculated based on the PA signals. The data
points were normalized against the 50-nm AuNCs at 5 min post injection. (C) Average
numbers of AuNCs accumulated in the SLNs dissected at 2 h post injection of the 30-nm
and 50-nm AuNCs, as measured by ICP-MS. Here NLNdenotes the number of AuNCs per
unit lymph node mass (g).
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PA images acquired before, 5 min, and 60 min after the injection of AuNCs (200 pM, 100
μL) with different surface charges. The PVP layer on the nanocages surface was replaced
with SH-PEG5000-X, X=OMe, NH2, or COOH to generate a neutral, positive, or negative
surface charge. (A, D, G) PA images before the injection of AuNCs: (B, E, H) PA images at
5 min post injection of AuNCs with different charges. SLNs started to appear except for the
case of AuNCs with positive charges. Some lymphatic vessels were also observed in the
case of AuNCs with negative charges; (C, F, I) PA images at 60 min after the injection of
AuNCs with different charges. BV, blood vessels; LV, lymphaticvessels; SLN, sentinel
lymph node.
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(A) PA signal enhancement in SLNs as a function of time post injection of AuNCs with
different surface charges: negative (blue line), positive (red line), and neutral (black line)
(n=3 rats for each group). (B) Average number of AuNCs accumulated in the SLN dissected
at 4 h post injection of AuNCs with different surface charges, as measured by ICP-MS (n=3
rats for each group). Here NLNdenotes the number of AuNCs per unit lymph node mass (g).
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PA images acquired (A) before, (B) 1 h, and (C) 72 h after the injection of AuNCs (500 pM,
100 μL), showing the transport of AuNCs from SLN to the second lymph node (LN2) and
third lymph node (LN3). (D) Ex vivo (i) PA image and (ii) photograph of dissected lymph
nodes containing AuNCs. The scale of the ruler is mm/div.
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Table 1
A sumamry of the hydrodynamic diameters and zeta-potentials of the AuNCs modified with different surface
groups.
Surface coating Hydrodynamic diameter (nm) Zeta-potentials (mV)
SH-PEG5000- OMe 89.4 ± 3.7 −7.2 ± 4.2
SH-PEG5000- NH2 93.7 ± 4.5 +12.5 ± 1.5
SH-PEG5000- COOH 92.0 ± 4.3 −16.8 ± 1.8
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